Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A once-daily GLP-1 receptor agonist FDA-approved for type 2 diabetes. Shorter-acting than semaglutide, with a stronger effect on postprandial glucose. Also available in a fixed-ratio combination with insulin glargine (Soliqua).
A GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management. One of the most commercially successful peptide drugs in history.
Activates GLP-1 receptors, stimulating glucose-dependent insulin secretion and suppressing glucagon. Its shorter duration of action produces a more pronounced effect on gastric emptying and postprandial glucose compared to longer-acting GLP-1 agonists.
Mimics the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system signaling. The result is improved blood sugar control and significant weight loss.
- Type 2 diabetes (adjunct to diet and exercise)
- Postprandial glucose control
- Combined with basal insulin (Soliqua)
- Weight management
- Type 2 diabetes treatment
- Blood sugar regulation
- Cardiovascular risk reduction
- Nausea and vomiting (common, usually transient)
- Diarrhea
- Headache
- Hypoglycemia when combined with sulfonylureas
- Pancreatitis (rare)
- Nausea and vomiting (common, usually transient)
- Pancreatitis (rare but serious)
- Gallbladder issues
- Potential thyroid tumor risk (animal studies)
- Muscle mass loss alongside fat loss
- GI side effects (diarrhea, constipation)
FDA-approved as Adlyxin (2016) for type 2 diabetes. Also available as Soliqua 100/33 (fixed-ratio combination with insulin glargine). Less weight loss than semaglutide but better postprandial control.
FDA-approved as Ozempic (diabetes, 2017), Wegovy (weight management, 2021), and Rybelsus (oral, diabetes, 2019). Multiple dosage forms and indications approved.
- Lixisenatide in type 2 diabetes (GetGoal trials)
2013 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.